COYA NASDAQ
Coya Therapeutics, Inc.
1W: -2.1%
1M: -17.3%
3M: +6.5%
YTD: -27.1%
1Y: -34.6%
3Y: -16.9%
$4.12
+0.17 (+4.30%)
Weekly Expected Move ±6.5%
$3
$4
$4
$4
$4
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' 8.95.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships13
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2023-03-22
Earliest Filing
2026-01-30
Latest Filing
investor: 6
partner: 6
acquirer: 1
Counterparties (Filed by COYA)
13 relationshipsCompanies named in COYA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Dr. Reddy's Labs | — | investor | Purchased $10.0 million of common stock in a private placement. | 2026-01-30 | View |
| Greenlight Capital | GLRE | investor | Purchased $1.1 million of common stock in a private placement. | 2026-01-30 | View |
| Lucid Capital Markets, LLC | LCID | acquirer | Underwriter for the public offering of common stock | 2025-10-27 | View |
| Allele Capital Partners, LLC | — | partner | Financial advisor to the Company through Wilmington Capital Securities, LLC | 2025-10-27 | View |
| Dr. Reddy's Laboratories Ltd. | RDY | partner | Amended development and license agreement for COYA 302 clinical trial funding and royalty adjustments. | 2024-06-05 | View |
| Dr. Reddy's Laboratories SA | RDY | partner | Affiliate of Dr. Reddy's Laboratories Ltd. involved in amending the development and license agreement. | 2024-06-05 | View |
| Alzheimer's Drug Discovery Foundation | — | investor | Private placement investor purchasing 603,136 shares of common stock for $5.0 million. | 2024-05-20 | View |
| Dr. Reddy's Laboratories Ltd. | RDY | partner | Entered into a Development and License Agreement for exclusive commercialization rights of COYA 302 in the New Territori | 2023-12-06 | View |
| Dr. Reddy's Laboratories SA | RDY | partner | Affiliate of Dr. Reddy's Laboratories Ltd. included in the Development and License Agreement. | 2023-12-06 | View |
| BTIG, LLC | — | investor | Acted as lead placement agent for the private placement offering. | 2023-12-06 | View |
| Allele Capital Partners, LLC | — | investor | Acted as financial advisor and received a warrant for the private placement offering. | 2023-12-06 | View |
| Chardan Capital Markets LLC | — | investor | Acted as financial advisor and received a cash fee for the private placement offering. | 2023-12-06 | View |
| Dr. Reddy's Laboratories Limited | RDY | partner | Exclusive License and Supply Agreement for COYA 302 development and commercialization | 2023-03-22 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-14 | Other Events | View | |
| 2026-10-05 | Other Events | View | |
| 2026-09-15 | Other Events | View | |
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-08-07 | Officer/Director Change | View | |
| 2026-06-25 | Shareholder Vote | View | |
| 2026-05-12 | Earnings Release; Other Events; Exhibits | View | |
| 2026-05-12 | Material Agreement; Exhibits | Agreement | View |
| 2026-04-02 | Officer/Director Change; Exhibits | View | |
| 2026-03-16 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-30 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2026-01-20 | Other Events | View | |
| 2026-01-08 | Other Events | View | |
| 2025-12-17 | Other Events | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-10-27 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-09-02 | Other Events | View | |
| 2025-08-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-07-29 | Other Events | View | |
| 2025-07-01 | Other Events | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR